Morgan Lewis Advises LEO Pharma on $1 Billion Acquisition
- date: 09/24/2009
- news source: Firm
NEW YORK, September 24, 2009: Warner Chilcott plc and LEO Pharma announced yesterday that, in exchange for a one-time cash payment of $1.0 billion to Warner Chilcott, LEO Pharma is re-acquiring Warner Chilcott's exclusive product licensing rights in the United States to its topical psoriasis treatments Taclonex®, Taclonex Scalp®, Dovonex® as well as rights to all products in LEO Pharma's development pipeline, and acquiring all inventories of the products. Morgan Lewis represented LEO Pharma on this transaction.
The Morgan Lewis team was led by Business & Finance partners Alan J. Neuwirth, Jonathan D. Morris, and R. Alec Dawson. Also on the team were Business & Finance partners Kenneth S. Kail, David G. Glazer and Associate Shawmir Naeem; FDA & Healthcare partner Kathleen M. Sanzo; and Intellectual Property partners Brian P. Murphy and Louis W. Beardell, Jr.
For additional details on the transaction, please visit:
Alan J. Neuwirth Kenneth S. Kail Louis W. Beardell, Jr. Shawmir Naeem Jonathan D. Morris Kathleen M. Sanzo R. A. Dawson David G. Glazer